A real-world study of acute and preventive medication use, adherence, and persistence in patients prescribed fremanezumab in the United States

Table 5 Subgroup analysis by presence of comorbid depression, anxiety, and hypertension

	Patients with migraine and comorbid depression cohort (n = 172)
	Baseline	Follow-up	P value
Total number of patients with antidepressant prescriptions, n (%)	118 (68.6)	97 (56.4)	*0.003*
Total number of antidepressant prescriptions, mean (SD)	1.05 (0.96)	0.84 (0.95)	*0.008*
	Patients with migraine and comorbid anxiety cohort (n = 180)
	Baseline	Follow-up	P value
Total number of patients with anxiolytic prescriptions, n (%)	99 (55.0)	85 (47.2)	*0.037*
Total number of anxiolytic prescriptions, mean (SD)	0.75 (0.88)	0.66 (0.81)	0.182
	Patients with migraine and comorbid hypertension cohort (n = 142)
	Baseline	Follow-up	P value
SBP, mean (SD)	127.3 (15.0)	127.0 (14.6)	0.837
DBP, mean (SD)	78.4 (10.0)	77.8 (10.6)	0.562

SD standard deviation, SBP systolic blood pressure, DBP diastolic blood pressure
P values calculated via McNemar’s test and the paired t-test or Wilcoxon signed rank test to dichotomous and continuous variables, respectively; bold, italicized P values indicate statistical significance

ISSN: 1129-2377